Kolb, E. Anders
March 6, 2014
Curriculum Vitae
Edward Anders Kolb, M.D.
Home Address:
804 Roberts Way
Kennett Square, PA 19348
Office Address:
Nemours Center for Cancer and Blood Disorders
Alfred I. duPont Hospital for Children
1600 Rockland Road
Wilmington, DE 19803
eakolb@nemours.org
Education:
1988-1992
1992-1996
BA, University of Pennsylvania, Philadelphia, PA (Biological Basis of Behavior)
MD, Jefferson Medical College, Philadelphia, PA
Postgraduate Training and Fellowship Appointments:
1996-1999
Resident in Pediatrics, St. Christopher’s Hospital for Children, Philadelphia, PA
1999-2001
Fellow in Pediatric Hematology and Oncology, Memorial Sloan-Kettering Cancer
Center, New York, NY
2000-2002
Research Fellow in Molecular Pharmacology, Memorial Sloan-Kettering Cancer
Center, New York, NY
2001-2002
Chief Fellow, Pediatric Hematology and Oncology, Memorial Sloan-Kettering
Cancer Center, New York, NY
Faculty Appointments:
2002-2004
Memorial Sloan-Kettering Cancer Center, New York, NY
Clinical Instructor, Pediatric Hematology and Oncology
2004-2007
Albert Einstein College of Medicine, Bronx, NY
Assistant Professor, Pediatrics, Division of Hematology and Oncology
2004-2007
The Children’s Hospital at Montefiore, Bronx, NY
Assistant Professor, Pediatrics, Division of Pediatric Hematology and Oncology
2013-Present
Associate Professor, Thomas Jefferson University, Jefferson Medical College
Hospital and Administrative Appointments:
2002-2004
Member, Pediatric Leukemia Service, Memorial Sloan-Kettering Cancer Center,
New York, NY
2002-2004
Member, Pediatric Stem Cell Transplantation Service, Memorial Sloan-Kettering
Cancer Center, New York, NY
2004-2007
Member, Albert Einstein Cancer Center, Albert Einstein College of Medicine,
Bronx, NY
2004-2007
Director, Pediatric Preclinical Chemotherapy Testing Laboratory, Albert Einstein
College of Medicine, Bronx, NY
2004-2007
Director, Pediatric Stem Cell Transplantation, The Children’s Hospital at
1
Kolb, E. Anders
2004-2007
2007-Present
2007-Present
2007-Present
2011-Present
2012-Present
2013-Present
March 6, 2014
Montefiore, Bronx, NY
Director, Pediatric Leukemia and Lymphoma Service, The Children’s Hospital at
Montefiore, Bronx, NY
Nemours Alfred I. duPont Hospital for Children, Wilmington, DE
Attending Physician, Pediatrics, Nemours Center for Cancer and Blood Disorders
Program Director, Blood and Bone Marrow Transplantation, Nemours Alfred I.
duPont Hospital for Children, Wilmington, DE
Head, Cancer Therapeutics Laboratory, Nemours Center for Childhood Cancer
Research, Wilmington, DE
Director, Nemours Center for Cancer and Blood Disorders, Nemours Alfred I.
duPont Hospital for Children, Wilmington, DE
Interim Director, Nemours Center for Childhood Cancer Research, Nemours
Alfred I. duPont Hospital for Children, Wilmington, DE
Chief, Division of Hematology and Oncology, Nemours Alfred I. duPont Hospital
for Children, Wilmington, DE
Specialty Certification:
2003 - Present Pediatric Hematology-Oncology (American Board of Pediatrics),
Licensed Physician:
1996-2001
Pennsylvania (MT039273T)
2001-2008
New York (#214133)
2007-present
Delaware (#C-10008378)
2012-present
Pennsylvania (MD446009)
Awards, Honors and Membership in Honorary Societies:
1996
J. Woodrow Savacool Award in Medical Ethics, Jefferson Medical College
1996
Alfred I. duPont Award in Pediatrics, Alfred I duPont Institute
1996
The E. Harold Hinnman Memorial Prize, Jefferson Medical College
1999
The Nancy Elizabeth Barnhart Memorial Award, St. Christopher’s Hospital for Children
1999
David S. Smith Housestaff Teaching Award, St. Christopher’s Hospital for Children
2000
Revson Fellow for Biomedical Research, Memorial Sloan-Kettering Cancer Center
2002
Merit Award, American Society of Clinical Oncology
2007
Member, Society for Pediatric Research
2010
Nemours Alfred I. duPont Hospital for Children, Physician of the Year
2011
Nemours, Physician Award for Excellence in Scholarship
2011
Leukemia & Lymphoma Society, Man of the Year Candidate (Runner-up)
2012
Resident Educator of the Month (March)
Membership in Professional and Scientific Societies:
2001-present
American Association of Cancer Research
2002-present
Children’s Oncology Group
2007-present
Society for Pediatric Research, Member
2007-present
American Society for Blood and Marrow Transplantation
2013-present
American Society of Hematology
2
Kolb, E. Anders
March 6, 2014
Professional and Scientific Committees:
Local
1999-2002
Graduate Medical Education Committee, Memorial Sloan-Kettering Cancer
Center
2001-2002
Quality Assessment Committee, Memorial Sloan-Kettering Cancer Center
2000-2004
Pediatric Pharmacy QA Subcommittee, Memorial Sloan-Kettering Cancer Center
2001-2004
Parent Bereavement Committee Member, Memorial Sloan-Kettering Cancer
Center
2002-2004
Pediatric Day Hospital Committee Member, Memorial Sloan-Kettering Cancer
Center
2003-2004
Junior Faculty Council Member, Memorial Sloan-Kettering Cancer Center
2004-2007
Residency Selection Committee, The Children’s Hospital at Montefiore
2004-2007
Chemotherapy Quality Assurance Committee, The Children’s Hospital at Montefiore
2004-2007
Stem Cell Transplant Medical Advisory Committee, The Children’s Hospital at
Montefiore
2007-Present
Bereavement Committee, Nemours Alfred I. duPont Hospital for Children
2007-Present
Spirituality and Healing Committee, Nemours Alfred I. duPont Hospital for Children
2007-Present
Cancer Committee, Nemours Alfred I. duPont Hospital for Children
2010-Present
Member, Nemours Institutional Animal Care and Use Committee
2010-Present
Member, Nemours Institutional Biosafety Committee
2010-Present
Chair, Nemours Alfred I. duPont Hospital for Children, Pharmacy and Therapeutics
Committee
2011-2012
Member, Nemours Nominating Committee for Physician Excellence Awards
2011-2012
Member, Nemours Search Committee for the Executive Director for Clinical
Research Services
2011-Present
Steering Committee, Delaware Bioinformatics Collaborative
2013-Present
Member, Nemours Strategy Council
2013-Present
Member, Nemours Guiding Council
National
2000-2002
2000-2002
2001-2003
2004-2007
2004-present
2004-Present
2005-2007
2010-Present
2011-Present
2011-Present
2011-Present
2012-Present
2012-Present
2012-Present
2013-Present
American Society of Clinical Oncology, Scientific Program Committee Member
American Society of Clinical Oncology, Career Development Committee
Alliance for Childhood Cancer, ASCO representative
Children’s Oncology Group, Member, Tcell ALL Working Group
Children’s Oncology Group, AALL0434 Study Committee Member
Member, Pediatric Preclinical Testing Program
Member of the Committee on Clinical Investigations, Albert Einstein College of
Medicine (AECOM IRB)
Chair, COG ADVL1014 Study Committee
Member, Children’s Oncology Group Bone Tumor Committee
Member, Children’s Oncology Group Ewing Sarcoma Working Group
Member, Children’s Oncology Group Osteosarcoma Working Group
Study Committee Member, Children’s Oncology Group AEWS1221
Scientific Council Member, Children’s Oncology Group
Sarcoma Alliance for Research through Collaboration, Concept Review Committee
Member
Chair, Myeloid Disease Committee, Children’s Oncology Group
3
Kolb, E. Anders
2013-Present
2013-Present
2013-Present
2013-Present
March 6, 2014
Study Committee Member, Children’s Oncology Group AOST1322
Study Committee Member, Children’s Oncology Group AAML1331
Data Safety and Monitoring Review Board, National Cord Blood Program, New York
Blood Center
Member-at-Large, Executive Committee, Pediatric Blood and Marrow Transplant
Consortium.
Editorial Positions:
Editorial Board Member – Clinical Cancer Research (2011 – present)
Editorial Board Member – Frontiers in Pediatric Oncology (2011-present)
Invited to review manuscripts for Adolescent and Young Adult Oncology, Apoptosis, Blood, Cancer
Research, Cell Biology and Toxicology, Clinical Cancer Research, Clinical
Orthopaedics and Related Research, European Journal of Cancer, European
Journal of Endocrinology, Expert Opinion on Drug Discovery, Expert Opinion on
Investigational Drugs, Hematologica, Immunotherapy, International Journal of
Cancer, Journal of Chemotherapy, Journal of Clinical Oncology, Journal of
Orthopedic Research, Journal of Pediatric Hematology and Oncology, Leukemia,
Molecular Cancer Therapeutics, Molecular Diagnosis and Therapy, Pediatric
Blood and Cancer, Pediatric Drugs, The Pharmacogenomics Journal, PLoS
Journal, Supportive Care in Cancer
Grant reviewer for:
Congressionally Directed Medical Research Programs, Leukemia and
Lymphoma Research UK, Cancer Research UK, Liddy Shriver Sarcoma
Foundation, St. Baldricks Foundation, The Andrew McDonough B+ Foundation
and the Bodhi Fund.
Major Teaching and Clinical Responsibilities:
Memorial Sloan-Kettering Cancer Center
2001-2002
Chief Fellow, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center
Responsible for coordinating the educational program for Pediatric Hematology
and Oncology Fellows.
2002-2004
Attending Physician on clinical service 9 weeks per year supervising residents
and medical students.
The Children’s Hospital at Montefiore
2004-2007
Attending Physician on clinical service 12 weeks per year supervising residents
and medical students.
2004-2007
Responsible for resident lectures on pediatric leukemia, lymphoma,
immunodeficiencies, transfusion medicine, and bone marrow transplant.
Nemours Alfred I. duPont Hospital for Children
2007-Present
Attending on Blood and Bone Marrow Transplantation Service at Nemours Alfred
I. duPont Hospital for Children supervising Thomas Jefferson University (TJU)
pediatric residents and medical students 40 weeks per year
4
Kolb, E. Anders
2007-Present
2007-Present
2007-Present
2008-Present
2009-Present
March 6, 2014
Attending on Hematology and Oncology Service at Nemours Alfred I. duPont
Hospital for Children supervising TJU pediatric residents and medical students 6
weeks per year
Responsible for resident lectures on pediatric immunodeficiencies and bone
marrow transplant.
Supervised resident and medical student research projects in the Cancer
Therapeutics Laboratory
Invited speaker for Hematology and Oncology Section of the annual Board
Review Course
Responsible for Bone Marrow Transplant Lectures for Gastroenterology, Critical
Care, Pulmonary and Immunology Fellows
Lectures by Invitation:
2004
Grand Rounds Long Island College Hospital, “Alloimmune Thrombocytopenia in
Fetuses and Neonates”
2004
Invited Speaker, The Children’s Hospital at Montefiore Alumni Day,
“Hematopoietic Stem Cell Transplantation in Children”
2005
Grand Rounds Brookdale Hospital, “Hematopoietic Stem Cell Transplantation in
Children”
2005
Grand Rounds Norwalk Health System “Leukemia and Hematopoietic Stem Cell
Transplantation in Children”
2005
Grand Rounds Stamford Health System “Hematopoietic Stem Cell
Transplantation in Children”
2006
Invited Keynote Speaker at the Annual Meeting of the New York Allergy and
Asthma Society “Hematopoietic Stem Cell Transplantation in Children.”
2006
Co-Chaired a series of national teleconferences on Relapsed and Refractory
Childhood ALL sponsored by Genzyme Oncology
2006
Hematology Grand Rounds, Montefiore Medical Center, “Diamond-Blackfan
Anemia”
2006
Invited Speaker – New York Hematology and Oncology Consortium. “Preclinical
Testing in Pediatrics.”
2007
Grand Rounds, Nemours Alfred I. duPont Hospital for Children– “Bone Marrow
Transplantation in Children”
2008
Grand Rounds Riddle Memorial Hospital – “Bone Marrow Transplantation in
Children”
2009
Invited Speaker, Pediatric Research Conference, Weill Cornell Medical College –
“IGF1R signaling in Osteosarcoma”
2010
Invited Speaker, Alex’s Lemonade Stand Foundation, Childhood Cancer
Symposium. “Bereavement Support”, Philadelphia, PA
2010
Invited Speaker, Lankenau Hospital, Department of Obstetrics and Gynecology
Grand Rounds. “Public Cord Blood Banking”
2011
Invited Speaker, Solving Kids Cancer, Webinar, “Oncolytic Virus Therapy in
Children.”
2011
Invited Speaker, Thomas Jefferson University, Department of Pediatrics Grand
Rounds, “Cord Blood Banking: rationale and patient counseling”
5
Kolb, E. Anders
2011
2011
2012
2013
March 6, 2014
Invited Speaker, American College of Osteopathic Obstetricians and
Gynecologist Annual Meeting, “Cord Blood Banking: rationale and patient
counseling”
Regional Meeting, Clinical Pediatric Oncology Nursing, “Cord Blood Banking:
rationale and patient counseling.”
Leukemia and Lymphoma Society, “Progress in Research for Leukemia and
Lymphoma.”
Invited Lecture: “Pediatric Leukemia and Bone Marrow Transplantation. del V
Congreso Nacional de Oncología, III Taller de Patología y III Jornadas de
Enfermería Oncológica
Bibliography:
Publications, Peer-Reviewed
1. Friedman D, Hu Z, Kolb EA, Gorfajn B, and Scotto KW. Ecteinascidin-743 inhibits activated but
not constitutive transcription. Cancer Res. 2002 62: 3377-3381
2. Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu
T, Wexler L, Wolden S, and Meyers PA. Long-term event-free survival after intensive
chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncology,
2003;21:3423-3430
3. Kolb EA, Steinherz PG. A new multidrug re-induction protocol with topotecan, vinorelbine,
thiotepa, dexamethasone, and gemcitabine (TVTG) for relapsed or refractory acute leukemia.
Leukemia, 2003;17:1967-1072.
4. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD,
Healey JG, Huvos AG, Goorin A, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D.
Phase II study of Ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Cancer, 2003;98:832-40.
5. Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Imatanib mesylate in Philadelphia chromosome
positive leukemia of childhood. Cancer, 2003;98:2643-50.
6. Hoang B, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza R, Meyers PA, Gorlick RG.
Dkk-3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-BetaCatenin Pathway. Cancer Res. 2004;64:2734-9
7. Berkowitz RL, Kolb EA, McFarland JG, Weisert M, Primani A, Lesser M, Bussel JB. Parallel
randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstetrics and
Gynecology, 2006 Jan;107(1):91-6.
8. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Gorlick R, Kolb EA, Zhang W, Lock
R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford
C, Zeidner J, Wu1 J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. The Pediatric
Preclinical Testing Program: Description of Models and Early Testing Results. Pediatric Blood
and Cancer, 2007 Dec;49(7):928-40.
9. Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, Healey JH, Huvos AG, Meyers PA,
Gorlick R. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and
plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer
Res. 2007 May 1;13(9):2557-67.
10. Garg V, Zhang WE, Kolb EA. ILX651 inhibits growth of pediatric sarcoma lines in vitro and in
vivo. Clin Cancer Res. 2007 Sep 15;13(18):5446-54
11. Scheinfeld MH, Lui YW, Kolb EA, Engel HM, Gomes WA, Weidenheim KM, Bello JA. The
neuroradiological findings in a case of Revesz syndrome. Pediatr Radiol. 2007
6
Kolb, E. Anders
March 6, 2014
Nov;37(11):1166-70.
12. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Gorlick R, Kolb EA, Zhang W, Lock
R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford
C, Zeidner J, Wu1 J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. Stage 1 Testing
of the Proteasome Inhibitor Bortezomib by the Pediatric Preclinical Testing Program. Pediatr
Blood Cancer. 2008 Jan;50(1):37-45
13. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M,
Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing of the VEGFR inhibitor AZD2171 by the
pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Mar;50(3):581-7
14. Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds
CP, Smith MA, Lock RB. .Initial testing of cisplatin by the pediatric preclinical testing program.
Pediatr Blood Cancer. 2008 May;50(5):992-1000
15. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP Maris JM, Keir ST,
Billups CA, Smith MA. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric
preclinical testing program. Pediatr Blood Cancer. 2008 Apr;50(4):799-805
16. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP Maris JM,
Keir ST, Billips CA, Smith MA. Initial testing of dasatinib by the pediatric preclinical testing
program. Pediatr Blood Cancer. 2008 Jun;50(6):1198-206.
17. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir
ST, Wu J, Smith M. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric
preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1181-9.
18. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Hernan C, Reynolds CP Maris JM, Keir
ST, Billips CA, Smith MA. Initial Testing (Stage 1) of a Monoclonal Antibody (SCH 717454)
against the IGF-1 Receptor by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2008 Jun;50(6):1190-7.
19. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST,
Wu J, Houghton. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor
alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood
Cancer. 2008 Jul;51(1):34-41
20. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP,
Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing
program. Pediatr Blood Cancer. 2008 Jul;51(1):42-8.
21. Gidwani P, Kolb EA. The combination of clofarabine and cytarabine in pediatric relapsed acute
lymphoblastic leukemia: a case report. Chemotherapy 2008;54:120-124.
22. Gidwani P, Levy A, Goodrich J, Weidenheim K, Kolb EA. Successful outcome with tandem
myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient
with atypical teratoid/rhabdoid tumor of the central nervous system. J Neurooncol.
2008;88(2):211-5.
23. Hingorani P, Zhang W, Piperdi S, Pressman L, Lin J, Gorlick R, Kolb EA. Preclinical activity of
palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant
osteosarcoma. Cancer Chemother Pharmacol. 2009;64(4):733-40.
24. Hingorani P, Zhang W, Gorlick R, Kolb EA. Inhibition of Src phosphorylation alters metastatic
potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res. 2009;15:3416-22.
25. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep.
2009;11:307-13.
26. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP,
Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the
7
Kolb, E. Anders
March 6, 2014
pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Sep;53(3):505-8.
27. Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang
MH, Maris JM, Billups C, Smith MA. Initial testing of aplidin by the pediatric pre-clinical testing
program. Pediatr Blood Cancer. 2009 Sep;53(3):509-12.
28. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST,
Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA. Initial testing (stage 1) of lapatinib
by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Oct;53(4):594-8.
29. Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir
ST, Billups CA, Smith MA. Initial testing (stage 1) of the kinesin spindle protein inhibitor
ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009;53:12551263.
30. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep.
2009 Jul;11(4):307-13.
31. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP,
Maris JM, Watkins AE, Houghton PJ. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by
the pediatric preclinical testing program. Pediatr Blood Cancer. 2009;54:307-310.
32. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir
ST, Watkins A, Smith MA, Lock RB. Initial testing of topotecan by the pediatric preclinical
testing program. Pediatr Blood Cancer. 2009;54:707-715
33. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir
ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA. Stage 2 Combination
Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Mol
Cancer Ther. 2010;9:101-112.
34. Kolb EA. Moving towards non-invasive assessments of prognosis in osteosarcoma. Pediatr
Blood Cancer. 2010 Apr;54(4):497-8.
35. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH,
Wu J, Smith MA, Houghton PJ. Initial testing of the aurora kinase a inhibitor MLN8237 by the
Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2010 2010;55(1):26-34
36. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu
J, Smith MA. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric
preclinical testing program. Pediatr Blood Cancer. 2010;54(7):921-6.
37. Hingorani P, Kolb EA. Past, present and future of therapies for pediatric sarcomas. Future
Oncol, 2010;6:605-618
38. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R. R1507, a
fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with
rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer, 2010;55:6775.
39. Bussel JB, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, Tsaur FW, Macfarland
JG.Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent
recurrence in the subsequent affected fetus. Am J Obstet Gynecol., 2010;203(2):135.e1-14
40. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu
J, Smith MA. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the
pediatric preclinical testing program. Pediatr Blood Cancer. 2010 May 5;55(2):295-303.
41. Morrissette JJD, de Chadarévian JP, Kolb EA. Familial Mosaic Monosomy 7 Syndrome (July,
2020). In: GeneReviews at GeneTests: Medical Genetics Information Resource [database
online]. Copyright, University of Washington, Seattle, 1997-2010. Available at
http://www.genetests.org.
8
Kolb, E. Anders
March 6, 2014
42. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH,
Watkins A, Houghton PJ, Smith MA. Initial testing (stage 1) of the multi-targeted kinase inhibitor
sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55(6):112633.
43. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C,
Smith MA, Houghton PJ, Lock RB. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the
pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55(7):1329-1337.
44. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D,
Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of AZD6244
(ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer.
2010;55:668-77.
45. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM,
Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011;56:595-603.
46. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds
CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA. Initial testing of the
hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood
Cancer. 2011;57:443-53.
47. Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang
MH, Phelps D, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the mTOR kinase
inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer,
2012;58:191-9
48. Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP,
Kang MH, Houghton PJ. Initial testing (stage 1) of the polyamine analog PG11047 by the
pediatric preclinical testing program. Pediatr Blood Cancer, 2011;57:268-74
49. Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL,
Billups CA, Smith MA, Houghton PJ. Initial testing of lenalidomide by the pediatric preclinical
testing program. Pediatr Blood Cancer, 2011;57:606-11.
50. Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA. Systemic administration of reovirus
(Reolysin) inhibits growth of human sarcoma xenografts. Cancer. 2011;117:1764-74.
51. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST,
Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA,
Lock RB. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A
inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother
Pharmacol. 2011;68(5):1291-304
52. Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST,
Carol H, Lock R, Maris JM, Wozniak A, Smith MA. Initial testing (Stage 1) of AT13387, an
HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer,
2012;59:185-8.
53. Morton CL, Maris JM, Keir ST, Gorlick R, Kolb EA, Billups CA, Wu J, Smith MA, Houghton PJ.
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric
preclinical testing program. Pediatr Blood Cancer, 2012;58:566-71.
54. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick
R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by
the pediatric preclinical testing program. Pediatr Blood Cancer, 2012;58:916-23.
9
Kolb, E. Anders
March 6, 2014
55. Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton
PJ. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin
by the pediatric preclinical testing program. Pediatr Blood Cancer, 2012;58:729-35.
56. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock
R, Maris JM, Billups CA, Smith MA. Initial testing (Stage 1) of LCL161, a SMAC mimetic, by the
pediatric preclinical testing program Pediatr Blood Cancer. 2012;58:636-9.
57. Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP,
Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ. Initial testing of JNJ26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer,
2012;59:329-32.
58. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang
MH, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) by the pediatric preclinical testing
program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer,
2012;58:815-8
59. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH,
Morton CL, Wu J, Smith PG, Yu J, Houghton PJ. Initial testing of the investigational NEDD8activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood
Cancer. 2012;59:246-53.
60. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R,
Keir ST, Carol H, Lock R, Billups CA, Smith MA. Initial testing (stage 1) of SGI-1776, a PIM1
kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer, 2012;59:74952.
61. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST,
Reynolds CP, Kang MH, Billups CA, Smith MA. Testing of the Akt/PKB inhibitor MK-2206 by the
pediatric preclinical testing program. Pediatr Blood Cancer. 2011;59(3):518-24.
62. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D,
Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the cyclin
dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
Pediatr Blood Cancer. 2012 Dec 15;59(7):1266-74. doi: 10.1002/pbc.24073.
63. Lettieri CK, Hingorani P, Kolb EA. Progress of oncolytic viruses in sarcomas. Expert Rev
Anticancer Ther., 2012;12:229-42.
64. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B,
Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing of the MDM2 inhibitor
RG7112 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Apr;60(4):63341. doi: 10.1002/pbc.24235.
65. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA,
Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing (Stage 1) of Eribulin, a
Novel Tubulin Binding Agent, by the Pediatric Preclinical Testing Program. Pediatr Blood
Cancer. 2013 Aug;60(8):1325-32
66. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL,
Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of temozolomide by the
pediatric preclinical testing program. Pediatr Blood Cancer. 2013 May;60(5):783-90.
67. Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA,
Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of ganetespib, an Hsp90
inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(7):E42-5
68. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris
JM, Billups CA, Houghton PJ, Smith MA. Initial testing (stage 1) of the phosphatidylinositol 3'
10
Kolb, E. Anders
March 6, 2014
kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood
Cancer. 2013;60(5):791-8..
69. Hingorani P, Dickman P, Garcia-Filion P, White-Collins A, Kolb EA, Azorsa DO. BIRC5
expression is a poor prognostic marker in Ewing sarcoma. Pediatr Blood Cancer. 2013
Jan;60(1):35-40. doi: 10.1002/pbc.24290.
70. Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, Bodhi P, Davis J, Davies
SM, Deconinck E, Deeg HJ, Duerst RE, Fasth A, Ghavamzadeh A, Giri N, Goldman FD, Kolb
EA, Krance R, Kurtzberg J, Leung WH, Srivastava A, Or R, Richman CM, Rosenberg PS,
Toledo Codina JS, Shenoy S, Socié G, Tolar J, Williams KM, Eapen M, Savage SA. Outcomes
of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenital. Biol
Blood Marrow Transplant. 2013 Aug;19(8):1238-43.
71. Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva
RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid
conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
Pediatr Blood Cancer. 2013 Nov;60(11):1860-7.
72. Sampson VB, Kamara DF, Kolb EA. Xenograft and genetically engineered mouse model
systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.
Expert Opin Drug Discov. 2013 Oct;8(10).
73. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA,
Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the polo-like kinase
inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood
Cancer. 2014 Jan;61(1):158-64.
74. Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MA. Initial testing
(Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric
preclinical testing program. Pediatr Blood Cancer. 2013 Sep 9. doi: 10.1002/pbc.24756. [Epub
ahead of print]
75. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris
JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R. Initial
testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the
Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2013 Sep 4. doi:
10.1002/pbc.24724. [Epub ahead of print]
Publications, non-peer reviewed:
1. Powell JL, Hingorani P, Grupp SA, Kolb EA. Hematopoietic Stem Cell Transplantation.
eMedicine from WebMD. Updated September 11, 2009. Available at:
http://emedicine.medscape.com/article/991032-overview.
Editorials, Reviews, Chapters, including participation in committee reports:
1. Kolb E.A., Bussel J.B. “Neonatal Alloimmune Thrombocytopenia Purpura,” In PA Gresele, J
Vermylen, CP Page (eds.) Platelets in Thrombotic and Non-thrombotic Disorders. Cambridge
University Press, 2002.
2. Kolb E.A., Gorlick RG. Childhood Leukemias. In: Thomas K. McInerny M, FAAP; Henry M.
Adam, MD, FAAP; Deborah E. Campbell, MD, FAAP; Deepak M. Kamat, MD, FAAP; and Kelly
J. Kelleher, MD, MPH, FAAP, editor. AAP Textbook of Primary Care: American Academy of
Pediatrics; 2008.AAP Textbook of Primary Care 5th Edition, in press
3. Levy AL, Kolb E.A. Anemia and Pallor. In: Thomas K. McInerny M, FAAP; Henry M. Adam,
MD, FAAP; Deborah E. Campbell, MD, FAAP; Deepak M. Kamat, MD, FAAP; and Kelly J.
11
Kolb, E. Anders
March 6, 2014
Kelleher, MD, MPH, FAAP, editor. AAP Textbook of Primary Care: American Academy of
Pediatrics; 2008.
Abstracts:
1. Shtil A.A., Kolb EA, Faircloth G., LaQuaglia M.P., Scotto K.W. “Ecteinascidin 743, a novel
natural cytotoxic compound, is a potent chemotherapeutic agent for human neuroblastoma and
rhabdomyosarcoma cell lines in vitro. (abstract #4353)” Poster Presentation at AACR, 2001
Annual Meeting.
2. Kolb EA, Laverdiere C, Gorlick R, Healey M, Kushner B, Wexler L, Wollner S, Meyers PA.
Long-term event-free survival (EFS) after intensive chemotherapy (CT) for Ewing’s family of
tumors (EFT) in children and young adults. Poster presentation at the 2002 ASCO Annual
Meeting. Merit Award Winner.
2. Laverdiere C, Kolb EA, Meyers P, Gorlick R, Maki R, Wexler L, Demetri G, Goorin A, Harmon
D, Jimeno J, Guzman C, Bagatell R. Phase II Study of ET-743 In Recurrent Osteosarcoma.
Poster presentation at the 2002 ASCO Annual Meeting.
3. Kolb EA, Berkowitz RL, McFarland JG, Bussel JB. Antenatal management of Alloimmune
Thrombocytopenia: A prospective, randomized, risk-based trial. Abstract #5178, 2002
American Society of Hematology, Oral Presentation.
4. Kolb EA, Scotto KW. Structure-function analysis of ET-743: Transcriptional activity, DNA
binding affinity, and cytotoxicity of ecteinascidin analogs. Abstract #105789, 2003 American
Association of Cancer Research, Poster Presentation.
5. Kolb EA, Mazza B, Yang R, Merola P, Sowers R, Healey J, Meyers PA, Huvos AG, Gorlick R.
Novel Murine Xenograft Models of Human Osteosarcoma and In Vivo Response to
Gemcitabine, L-Alanosine (SDX-102), and Herceptin. Abstract #1042, 2004 American
Association of Cancer Research, Poster Presentation.
6. Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R,
Kolb EA, Keshelava N, Reynolds CP, Morton C, Smith MA. Evaluation of Bortezomib against
Childhood Tumor Models by the Pediatric Preclinical Testing Program (PPTP). Poster
Presentation, EORTC, 2005
7. Zhang WE, Kolb EA. ILX651 inhibits growth of pediatric sarcoma lines in vitro and in vivo.
2005 American Association of Cancer Research Annual Meeting.
8. Kolb EA, Chou AJ, Zhang WE, Steinherz PG, Gorlick RG, Meyers PA. The mTOR inhibitor,
rapamycin, inhibits growth of Ewing’s sarcoma in vitro and in vivo. 2005 American Association
of Cancer Research Annual Meeting.
9. Kolb EA, Garg V, Meyers PA, Gorlick RG. The combination of gemcitabine and docetaxel has
significant anti-tumor activity in osteosarcoma, rhabdomyosarcoma and Ewing’s sarcoma cell
lines. 2005 Connective Tissue Oncology Society Annual Meeting.
10. Zhang WE, Kolb EA. Reolysin(R), an unmodified Reovirus, has significant anti-tumor activity
in childhood sarcomas. Poster Presentation, AACR Annual Meeting, 2006.
11. Kolb EA, Gidwani P, Gale RP, Gorlick RG. “A Preclinical Evaluation of ZIO-201
(Isophosphoramide Mustard (IPM)-Lysine) in sarcoma.” Oral Presentation at 2006 Connective
Tissue Oncology Society Annual Meeting.
12. Houghton PJ, Maris JM, Friedman HS, Keir ST, Lock RB, Gorlick R, Kolb EA, Reynolds CP,
Morton C and Smith MA. Pediatric preclinical testing program (PPTP) evaluation of the KSP
inhibitor Ispinesib (SB-715992). European Journal of Cancer Supplements, 4, 98 (2006).
13. Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Kolb EA, Keshelava N, Reynolds CP,
Morton C and Houghton PJ. Pediatric Preclinical Testing Program (PPTP) evaluation of the
12
Kolb, E. Anders
March 6, 2014
Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements, 4, 100
(2006).
14. Smith MA, Maris JM, Keir ST, Lock RB, Gorlick R, Kolb EA, Keshelava N, Reynolds CP,
Morton C and Houghton PJ. Pediatric Preclinical Testing Program (PPTP) evaluation of the
VEGFR-2 Inhibitor AZD2171. European Journal of Cancer Supplements, 4, 34 (2006).
15. Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R,
Kolb EA, Keshelava N, Reynolds CP, Morton C, Smith MA. Evaluation of 17dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against
Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP). Poster
Presentation, AACR, 2006
16. Benjamin R, Kolb EA, Gorlick R, Gale RP. Phase-1/-2 study of ZIO-201 (isophosphoramide
mustard (IPM)-lysine) in advanced sarcoma. Oral Presentation, Connective Tissue Oncology
Society, 2006.
17. Kolb EA, Gidwani P, Gale RP, Gorlick R. A preclinical Evaluation Of ZIO-201
(ISOPHOSPHORAMIDE Mustard (IPM)-lysine) In Sarcoma. Oral Presentation, Connective
Tissue Oncology Society, 2006.
18. Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R,
Kolb EA, Keshelava N, Reynolds CP, Morton C, Smith MA. Pediatric Preclinical Testing
Program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG.
Poster Presentation, ASCO, 2006.
19. Gidwani P, Zhang E, Gorlick R, Kolb EA. Dasatinib inhibits the growth, adhesion, and
migration of osteosarcoma cell line in vitro. Poster Presentation, AACR, 2007.
20. Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R, Kolb
EA, Keshelava N, Reynolds CP, Morton C, Houghton PJ. Pediatric Preclinical Testing Program
(PPTP) evaluation of the Bcl-2 inhibitor ABT- 263. Mini-Symposia, AACR Annual Meeting,
2007
21. Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R, Kolb
EA, Keshelava N, Reynolds CP, Morton C, Houghton PJ. Pediatric Preclinical Testing Program
(PPTP). Evaluation of the Fully Human Anti-IGF-1R Antibody SCH 717454. Poster
Presentation, EORTC, 2007
22. Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R,
Kolb EA, Keshelava N, Reynolds CP, Morton C, Smith MA. Initial Testing of the Histone
Deacetylase Inhibitor Vorinostat by the Pediatric Preclinical Testing Program. Poster
Presentation, EORTC, 2007
23. Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R,
Kolb EA, Keshelava N, Reynolds CP, Morton C, Smith MA. Pediatric Preclinical Testing
Program (PPTP) Evaluation of the EGFR and ErbB2 Inhibitor Lapatinib. Poster Presentation,
EORTC, 2007.
24. Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M, Gorlick R,
Kolb EA, Keshelava N, Reynolds CP, Morton C, Smith MA. Pediatric Preclinical Testing
Program (PPTP) Evaluation of the Multi-Targeted Kinase Inhibitor Sunitinib. Poster
Presentation, AACR, 2007
25. Morton C, Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M,
Gorlick R, Kolb EA, Keshelava N, Reynolds CP, Smith MA. Pediatric Preclinical Testing
Program (PPTP) Evaluation of the mTOR Inhibitor Rapamycin. Poster Presentation, AACR,
2007
13
Kolb, E. Anders
March 6, 2014
26. Carol H, Morton CL, Houghton PT, Maris JM, Friedman HS, Keir ST, Gorlick R, Kolb EA, Smith
MA, Lock RB. Pediatric Preclinical Testing Program (PPTP) evaluation of the topoisomerase I
inhibitor topotecan. AACR, 2008
27. Houghton PJ, Morton CL, Maris JM, Courtright J, Carol H, Lock RB, Friedman HS, Keir ST,
Gorlick R, Kolb EA, Reynolds CP, Kang M, Smith MA. Pediatric preclinical testing program
(PPTP) evaluation of the Aurora A kinase inhibitor MLN8237. AACR, Poster Presentation,
2008
28. Smith MA, Morton CL, Maris JM, Courtright J, Kolb EA, Gorlick R, Carol H, Lock RB, Friedman
HS, Keir ST, Kang M, Reynolds CP, Houghton PJ. Pediatric preclinical testing program (PPTP)
evaluation of the MEK1/2 inhibitor AZD6244 (ARRY-142886). AACR, Poster Presentation,
2008
29. Gidwani P, Zhang Z, Guha G, Liu L, Kolb EA. Reolysin in Combination with Radiation for
Pediatric Sarcomas. Poster Presentation, AACR, 2008
30. Gidwani P, Zhang E, Gorlick R, Kolb EA. Dasatinib does not inhibit the development of
pulmonary metastases in osteosarcoma. Mini Symposia, AACR, 2008
31. Morton C, Houghton PJ, Maris JM, Gorlick R, Kolb EA, Reynolds CP, Smith MA. Pediatric
Preclinical Testing Program (PPTP) evaluation of the oncolytic picornavirus, NTX-010 (SVV001). Poster Presentation, EORTC, 2008
32. Kolb EA, Morton C, Houghton PJ, Maris JM, Friedman HS, Keir ST, Gorlick R, Kang M,
Reynolds CP, Smith MA. Pediatric Preclinical Testing Program (PPTP) Evaluation of the Fully
Human anti-IGF-1R Antibody IMC-A12, Poster Presentation, EORTC, 2008
33. Kamara D, Sol-Church K, Zhang E, Gorlick R, Kolb EA. Targeting IGF-1 signaling in
osteosarcoma with the humanized monoclonal anti-IGF1R antibody R1507. Poster
Presentation, AACR, 2009 Annual Meeting
34. Carol H, Lock RB, Houghton PJ, Morton CL, Maris JM, Courtright J, Kolb EA, Gorlick R,
Friedman HS, Keir ST, Kang M, Reynolds CP, Smith MA. Pediatric preclinical testing program
(PPTP) evaluation of the Akt inhibitor GSK690693 . Poster Presentation, AACR, 2009 Annual
Meeting
35. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Carol H, Lock RB,
Friedman HS, Keir ST, Kang M, Reynolds CP, Smith MA. Pediatric Preclinical Testing Program
(PPTP) evaluation of the novel polyamine analogue PG11047. Poster Presentation, AACR,
2009 Annual Meeting
36. Morton C, Houghton PJ, Maris JM, Keir ST, Friedman HS, Lock RB, Carol H, Tajbakhsh M,
Gorlick R, Kolb EA, Keshelava N, Reynolds CP, Smith MA. Pediatric Preclinical Testing
Program (PPTP) evaluation of PR-104. Poster Presentation, AACR, 2009 Annual Meeting
37. Kolb EA, Gorlick R, Houghton PJ, Morton C, Maris JM, Courtright J, Carol H, Lock RB,
Friedman HS, Keir ST, Kang M, Reynolds CP, Smith MA. Pediatric Preclinical Testing
Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sorafenib. Poster
Presentation, AACR, 2009 Annual Meeting.
38. Houghton PJ, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb
EA, Kang M, Reynolds CP, Morton CL, Smith MA. Pediatric Preclinical Testing Program
(PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR kinase, EORTC, 2009.
39. Smith MA, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb
EA, Kang M, Reymolds CP, Morton CL, Houghton PJ. Pediatric Preclinical Testing Program
(PPTP): Evaluation of the MEK1/2 Inhibitor AZD6244 against Juvenile Pilocytic Astrocytoma
(JPA) Xenografts
14
Kolb, E. Anders
March 6, 2014
40. Kamara D, Zhang WE, Baker L, Gorlick R, Kolb EA. Resistance to IGF-1R inhibition by the
human monoclonal antibody R1507 may be mediated by EGFR in osteosarcoma. Poster
Presentation, 2009 Annual Meeting of the Connective Tissue Oncology Society
41. Sol-Church K, Stabley DL, McCahan SM, Kamara D, Kolb EA. Analysis of the Molecular
Factors Controlling Human Osteosarcoma Response to Chemotherapy. Poster Presentation,
ASHG, 2009
42. Powell, J.L., Frantz, C.N., Kolb, E.A. Reduced intensity allogeneic bone marrow
transplantation without inclusion of total body irradiation in a child with dyskeratosis congenita.
American Society of Bone Marrow Transplant, 2010 Annual Meeting
43. Powell, J.L., Savo, A.M., Furuya, K.N., Consolini, D.M., Malatack, J., Raab, C.P., Dunn, S.P.,
Kolb, E.A. Orthotopic liver transplant followed by a double cord blood transplant in a child with
erythropoietic protophoryria. American Society of Bone Marrow Transplant, 2010 Annual
Meeting
44. McCahan SM, Stabley DL, Kamara D, Holbrook J, Sol-Church K, Kolb EA. Digital Gene
Expression of miRNA in Osteosarcoma Xenografts: Finding Biological Relevance in miRNA
High Throughput Sequencing Data. Association of Biomolecular Resource Facilities, 2010
Annual Meeting.
45. Sowers R, Chung SH, Zhang WE, Kolb EA, Gorlick R. Responsiveness to IGF-1R targeted
therapy in osteosarcoma may be regulated by the 3179 G>A mutation. American Association
of Cancer Research, 2010 Annual Meeting.
46. Houghton PJ, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb
EA, Kang M, Reynolds CP, Morton CL, Smith MA. Pediatric preclinical testing program (PPTP)
stage 1 evaluation of BMS-754807 IGF-1 receptor inhibitor. American Association of Cancer
Research, 2010 Annual Meeting.
47. Smith MA, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb
EA, Kang M, Reymolds CP, Morton CL, Houghton PJ. Pediatric Preclinical Testing Program
(PPTP) evaluation of the CDK inhibitor SCH 727965. American Association of Cancer
Research, 2010 Annual Meeting.
48. Kolb EA, Kamara D, Stabley D, Zhang W, Hingorani P, Gorlick R, Sol-Church K. A SNP at 216 of the EGFR predicts EGFR-IGF1R cross-talk and resistance to IGF1R inhibition in
osteosarcoma. Oral Presentation, 2010 Annual Meeting Connective Tissue Oncology Society.
49. Keir ST, Morton C, Kolb EA, Gorlick R, Hernan C, Lock RB, Kang M, Reynolds P, Maris JM,
Wu J, Smith MA, Houghton PJ. Pediatric Preclinical Testing Program Evaluation of the DNA
Methylating Agent Temozolomide. American Association of Cancer Research, 2011 Annual
Meeting.
50. Carol H, Lock RB, Maris JM, Courtright J, Friedman HS, Keir ST, Gorlick R, Kolb EA, Kang M,
Reynolds CP, Smith PG, Thomas M, McDonald A, Houghton PJ, Smith MA. Pediatric
Preclinical Testing Program Evaluation of NEDD8-Activating Enzyme (NAE) Inhibitor MLN4924.
American Association of Cancer Research, 2011 Annual Meeting.
51. Houghton PJ, Lock RB, Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang
M, Maris JM, Billips CA, Smith MA. Pediatric Preclinical Testing Program Evaluation of the
Non-Camptothecin Topoisomerase 1 Targeted Agent Genz-644-282. American Association of
Cancer Research, 2011 Annual Meeting.
52. Kolb E, Zhang WE, Lewis JJ, Gorlick R. Palifosfamide, a Bifunctional DNA Alkylator, Inhibits
Growth of Pediatric Osteosarcoma Xenografts Across a Wide Dose Range Following Oral and
Parenteral Dosing. Oral Presentation, 2011 Annual Meeting of the Connective Tissue
Oncology Society, Chicago, IL.
15
Kolb, E. Anders
March 6, 2014
53. Sampson V, Kamara D, Calio B, Kolb EA. Reovirus as a potential therapy for malignant
peripheral nerve sheath tumor. American Association of Cancer Research, 2012 Annual
Meeting.
54. Houghton, PJ, Kang M, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir
ST, Billups CA, Kurmasheva RT, Smith MA. Pediatric Preclinical Testing Program (PPTP)
stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel. American
Association of Cancer Research, 2013 Annual Meeting.
55. Smith MA, Kang M, Reynolds CP, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA,
Kurmasheva RT, Houghton, PJ. Pediatric Preclinical Testing Program (PPTP) stage 1
evaluation of NSC750854, a sulfamated purine analog with a distinctive anticancer activity
profile. American Association of Cancer Research, 2013 Annual Meeting.
56. Houghton, PJ, Kang M, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir
ST, Billups CA, Kurmasheva RT, Smith MA. Pediatric preclinical testing program (PPTP) stage
1 evaluation of MLN0128, a potent TOR kinase inhibitor. American Association of Cancer
Research, 2013 Annual Meeting.
57. Robbins KM, Stabley DL, Conard K, Wu DJ, Stitik H, Kolb EA, Napper A, Mason RW, Gripp
KW, Sol-Church K. Uniparental disomy is associated with embryonal rhabdomyosarcoma in
Costello Syndrome and nonsyndromic patients. American Association of Cancer Research,
2013 Annual Meeting.
58. Cartledge DM, Drake KM, Gripp KW, Sol-Church K, Kolb EA, Napper AD. High-throughput
screen to identify compounds targeted to embryonal rhabdomyosarcoma harboring mutant
HRAS using cells derived from a pediatric Costello syndrome patient. American Association of
Cancer Research, 2013 Annual Meeting
59. Houghton, PJ, Kang M, Reynolds CP, Gorlick R, Kolb EA, Maris JM, Keir ST, Carol H, Lock
RB, Billups CA, Kurmasheva RT, Landesman Y, Shacham S, Kauffman M, Smith MA.
Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the XPO1/CRM1 inhibitor
KPT-330. American Association of Cancer Research, 2013 Annual Meeting
60. Smith MA, Kang M, Reynolds CP, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA,
Kurmasheva RT, Houghton, PJ. Pediatric Preclinical Testing Program (PPTP) stage 1
evaluation of cabozantinib. American Association of Cancer Research, 2013 Annual Meeting.
Community Service:
1999-present
Volunteer Attending Physician, Happiness is Camping – a camp for children with
cancer
2001-2007
Group Leader/Facilitator for the Towards Tomorrow Bereavement Group for
parents who have lost children to cancer, Memorial Sloan-Kettering Cancer
Center
2009-present
Group Leader/Facilitator for Bereavement Group for parents who have lost
children to cancer, Nemours Alfred I. duPont Hospital for Children
2009-present
Board of Directors, Leukemia Lymphoma Society, Delaware Chapter
2009-present
Board of Directors, Medical Director, Mason Shaffer Foundation
2011-present
President, Leukemia Lymphoma Society, Delaware Chapter
2011-present
Willowdale Chapel, Special Needs Ministry Medical Director
Research Support
Ongoing research support:
16
Kolb, E. Anders
March 6, 2014
U10 CA098543-11 (Adamson)
4/16/13-2/28/14
1.2 calendar months
National Institute of Health (NIH)
$27,973
Children’s Oncology Group Chairs Grant
This subcontract support is for the participation in the Children’s Oncology Group scientific leadership
and oversight as Chair of the Myeloid Disease Committee.
U10 CA098543-11 (Adamson)
3/1/13-2/28/14
0.6 calendar months
National Institute of Health (NIH)
$11,501
Children’s Oncology Group Chairs Grant
This subcontract support is for the participation in the Children’s Oncology Group scientific leadership
and oversight as Study Chair of the ADVL1014 Study.
Unnumbered award (Kolb)
7/1/13 – 6/30/14
0.6 calendar months in-kind
Sunshine Project
$60,000
Microtubule inhibitors in pediatric sarcomas, biomarkers for response and resistance.
The goal of this study is to understand the mechanism of response and resistance to microtubule
inhibitors in pediatric sarcomas with a focus on recently approve novel microtubule inhibitors.
1U10CA176879-01 (Sandler)
6/1/13 – 5/31/15
1.2 calendar months
National Institute of Health (NIH)
$1,166,000
Nemours Community Clinical Oncology Program
The goal of this infrastructure grant is to establish a Community Clinical Oncology Program inclusive
of all Nemours locations. The focus of the grant will be improved accrual to NCI-funded cancer
treatment and control trials.
N01-CM-91003-03 (Houghton)
11/30/09 – 10/31/14
0.96 calendar months
National Institute of Health (NIH)
$84,912
Pediatric Preclinical Testing Program
The goal of this study is to establish and maintain osteosarcoma xenografts to provide a thorough
preclinical evaluation of new agents prior to clinical trials in children
Unnumbered award (Kolb)
7/1/13-6/30/18
1.2 calendar monts in-kind
Leukemia Research Foundation of Delaware
$200,000
Preclinical Models for Pediatric Leukemia
The goal of this project is to develop xenograft models of pediatric leukemia from patient samples
Unnumbered award (Kolb)
1.2 calendar monts in-kind
7/1/11-12/31/13
17
Kolb, E. Anders
March 6, 2014
Nemours Intramural Cluster Grant
$150,000
“Rasopathy Cluster Grant”
The goal of this project is to identify therapeutic options for patient with Rasopathy.
Completed research projects
Unnumbered award (Kolb, PI ADVL1014) – 5% effort and support
12/8/11-7/31/12
National Childhood Cancer Foundation
“ADVL1014 – ADVL1014, A Phase I dose escalation study of REOLYSIN, a replication competent
reovirus, in pediatric patients with relapsed or refractory solid tumors.”
unnumbered award (Kolb, PI)
4/10/09 – 3/31/11
Nemours Intramural Grant
Phosphoprotein mapping of post-translation kinase activity in osteosarcoma xenografts following
treatment with R1507, a fully human anti-IGF-IR antibody
The goal of this project is to evaluate cell signaling responses to IGF1R inhibition in osteosarcoma.
Role: PI
unnumbered award
4/1/10-3/31/10
The Sarcoma Foundation of America
“Crosstalk between EGFR and IGF1 R mediated by polymorphisms in the EGFR promoter as a
mechanism for resistance to IGF1 R directed therapy in osteosarcoma”
The goal of this project is to define the mediators of cross-talk between EGFR and IGF1R
Role: PI
N01-CM-42216 (Kolb, PI subcontract)
09/04 – 09/09
NIH
Pediatric Preclinical Testing Program
The goal of this project is to investigate the preclinical testing of novel agents for use in pediatric
malignancies.
Role: co-PI (of subcontract)
unnumbered award (Kolb, PI)
12/08 – 12/09
FOSTER Foundation
R1507, a Fully Human Anti-IGF1R Antibody in Osteosarcoma Xenografts
The goal of this project is to evaluate the role of R1507 in Osteosarcoma xenografts.
Role: PI
unnumbered award (Kolb, PI)
01/05 – 12/07
Oncolytics Contract
Reolysin® in Xenografts of Human Osteosarcoma
The goal of this project is to evaluate the preclinical activity of Reovirus as a therapeutic agent in
pediatric sarcomas.
Role: PI
unnumbered award (Kolb, PI)
ILEX Contract
ILEX 651 in Solid Tumor of Childhood
01/05 – 12/07
18
Kolb, E. Anders
March 6, 2014
The purpose of this project is to evaluate the preclinical activity of tasitodin (ILEX651) in pediatric
sarcomas.
Role: PI
unnumbered award (Kolb, PI
07/01 – 6/02
Albert Einstein College of Medicine, Intramural award
“mTor inhibitors in Pediatric Solid Tumors”
The goal of this project was to evaluate the efficacy and mechanism of resistance of rapamycin in
pediatric solid tumor xenografts
Role: PI
unnumbered award (Kolb, PI)
Revson Foundatioin
Fellowship for Biomedical Research
The goal of this project was to complete preclinical testing on ET-743
Role: PI
07/01 – 6/02
19